В Я Мельниченко

614 total citations
22 papers, 222 citations indexed

About

В Я Мельниченко is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, В Я Мельниченко has authored 22 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 3 papers in Genetics. Recurrent topics in В Я Мельниченко's work include Multiple Sclerosis Research Studies (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Polyomavirus and related diseases (7 papers). В Я Мельниченко is often cited by papers focused on Multiple Sclerosis Research Studies (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Polyomavirus and related diseases (7 papers). В Я Мельниченко collaborates with scholars based in Russia, United States and Italy. В Я Мельниченко's co-authors include Denis A. Fedorenko, Tatyana Ionova, Andrei A. Novik, Pier Luigi Zinzani, Laura Maria Fogliatto, Alexander Kulagin, Patricia Marinello, Muhıt Özcan, Kozlov Va and Alejandro Majlis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

В Я Мельниченко

16 papers receiving 212 citations

Peers

Countries citing papers authored by В Я Мельниченко

Since Specialization

Citations

This map shows the geographic impact of В Я Мельниченко's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by В Я Мельниченко with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites В Я Мельниченко more than expected).

Fields of papers citing papers by В Я Мельниченко

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by В Я Мельниченко. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by В Я Мельниченко. The network helps show where В Я Мельниченко may publish in the future.

Co-authorship network of co-authors of В Я Мельниченко

This figure shows the co-authorship network connecting the top 25 collaborators of В Я Мельниченко. A scholar is included among the top collaborators of В Я Мельниченко based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with В Я Мельниченко. В Я Мельниченко is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development and Testing of Electronic Patient-Reported Outcome System “Health – Electronic Self-Assessment” (HESA) for Monitoring the Health Status of Patients with Hematologic Malignancies Based on Their Quality-of-Life Data 2024 ·SHILAP Revista de lepidopterología ·(unknown), В Я Мельниченко, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Tatyana Ionova	0
2	ANALYSIS OF THE EFFICIENCY OF USING DIFFERENT TECHNICAL MEANS FOR CREATING VIDEO LECTURES IN THE EDUCATIONAL PROCESS 2024 ·Innovate Pedagogy ·(unknown), В Я Мельниченко	1
3	Use of electronic patient-reported outcome system in routine clinical practice in patients with lymphoproliferative neoplasms undergoing autologous hematopoietic stem cell transplantation: a feasibility study 2024 ·(unknown), В Я Мельниченко, Denis A. Fedorenko, (unknown), А. А. Банникова, В. А. Богатырев, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Esther Natalie Olíva, (unknown), Sam Salek, Tatyana Ionova	0
4	Using Digital Technologies for Monitoring Patient’s Well-being and Quality of Life 2023 ·(unknown), Sergey Efremov, В Я Мельниченко, (unknown), Tatyana Ionova	1
5	Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL) 2023 ·Hematological Oncology ·Andrew McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, В Я Мельниченко, Heidi Móciková, Muhıt Özcan, Caterina Patti, (unknown), (unknown), (unknown), Jiřı́ Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, Kristen Ryland, Samhita Chakraborty, Wojciech Jurczak	0
6	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma: Final Analysis of KEYNOTE-170 2023 ·Blood ·Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Maria Fogliatto, Alejandro Martı́n, Beth Christian, Zafer Gülbaş, Muhıt Özcan, Guilherme Fleury Perini, Hervé Ghesquières, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand	31
7	Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma 2023 ·Blood ·Andrew McDonald, Estelle Verburgh, Manuel Gotti, Antonio Pinto, Jan Maciej Zaucha, Vladimir Ivanov, В Я Мельниченко, Heidi Móciková, Muhıt Özcan, Caterina Patti, (unknown), (unknown), (unknown), Jiřı́ Mayer, Güray Saydam, Sarah Tomassetti, Kumudu Pathiraja, (unknown), Patricia Marinello, Wojciech Jurczak	1
8	Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL) 2021 ·Blood ·Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Krimo Bouabdallah, (unknown), Alejandro Majlis, Laura Maria Fogliatto, Alejandro Martı́n, Beth Christian, Zafer Gülbaş, Muhıt Özcan, Guilherme Fleury Perini, Gilles Salles, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand	5
9	Autologous hematopoietic stem cell transplantation with low-intensity conditioning regimens in relapsing remitting multiple sclerosis: clinical outcomes and quality of life 2021 ·В Я Мельниченко, Denis A. Fedorenko, (unknown), (unknown), (unknown), Tatyana Ionova	0
10	Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study 2020 ·Blood ·Pier Luigi Zinzani, В Я Мельниченко, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Maria Fogliatto, Dolores Caballero, Beth Christian, Zafer Gülbaş, Muhıt Özcan, Gilles Salles, Margaret A. Shipp, Seth Thompson, Robert Orlowski, Patricia Marinello, Philippe Armand	1
11	KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL). 2020 ·Journal of Clinical Oncology ·John Kuruvilla, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz‐Kozik, Robin Gasiorowski, Nathalie A. Johnson, В Я Мельниченко, Laura Maria Fogliatto, (unknown), (unknown), Valéria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Sergey Alekseev, Iryna Kryachok, Naohiro Sekiguchi, Ying Zhu, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani	23
12	Diagnostic and Prognostic Value of Biochemical Markers of Infectious Complications of High-Dose Therapy with Autologous Hematopoietic Stem Cell Transplantation in Malignant Lymphoproliferative Diseases 2017 ·Clinical oncohematology ·(unknown), (unknown), В Я Мельниченко	3
13	Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B‐cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE‐170 phase 2 trial 2017 ·Hematological Oncology ·Pier Luigi Zinzani, Catherine Thiéblemont, В Я Мельниченко, Dzhelil Osmanov, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Maria Fogliatto, (unknown), Christian Bach, Zafer Gülbaş, Muhıt Özcan, Gilles Salles, Margaret A. Shipp, Arun Balakumaran, Sabine Chlosta, Arkendu Chatterjee, Philippe Armand	16
14	АНЕМИЧЕСКИЙ СИНДРОМ В КЛИНИЧЕСКОЙ ПРАКТИКЕ: ПРИНЦИПЫ ДИАГНОСТИКИ 2015 ·SHILAP Revista de lepidopterología ·(unknown), В Я Мельниченко, Denis A. Fedorenko	1
15	Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician’s and patient’s perspectives 2015 ·Annals of Hematology ·(unknown), (unknown), Tatyana Ionova, В Я Мельниченко, Denis A. Fedorenko, (unknown), (unknown), Andrei A. Novik	52
16	Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis 2012 ·Experimental Hematology ·(unknown), (unknown), Tatyana Ionova, В Я Мельниченко, Denis A. Fedorenko, (unknown), (unknown), (unknown), Andrei A. Novik	43
17	Reduced Intensity Conditioning Regimen of Autologous Hematopoietic Stem Cell Transplantation±Mitoxantrone Consolidation In Multiple Sclerosis 2010 ·Blood ·Andrei A. Novik, (unknown), В Я Мельниченко, Denis A. Fedorenko, (unknown), Tatyana Ionova, (unknown), (unknown)	1
18	High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis 2008 ·Experimental Hematology ·(unknown), Andrei A. Novik, (unknown), B. V. Аfanasiev, Igor Lisukov, Kozlov Va, (unknown), Tatyana Ionova, В Я Мельниченко, Denis A. Fedorenko, Alexander Kulagin, (unknown), Roman Ivanov, (unknown)	39
19	Treatment Outcomes in Multiple Sclerosis (MS) Patients after Early, Conventional and Salvage High Dose Chemotherapy (HDCT)+Autologous Stem Cell Transplantation (ASCT). 2005 ·Blood ·(unknown), Andrei A. Novik, B. V. Аfanasiev, Igor Lisukov, Tatyana Ionova, (unknown), (unknown), (unknown), В Я Мельниченко, Sergey Voloshin, Denis A. Fedorenko, (unknown), (unknown), (unknown), (unknown)	1
20	183Clinical and quality of life monitoring in multiple sclerosis patients undergoing high dose chemotherapy and autologous stem cell transplantation 2003 ·Biology of Blood and Marrow Transplantation ·Andrei A. Novik, Tatyana Ionova, Igor Lisukov, (unknown), (unknown), (unknown), В Я Мельниченко, (unknown), (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact